Experimental drug ST-001 nanoFenretinide for small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This phase 1 trial tests an experimental drug called ST-001 nanoFenretinide for people with small cell lung cancer that has returned or not responded to standard chemotherapy. The drug is a newer form of fenretinide, which is related to vitamin A, and may work differently to attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer (SCLC).
- You must have had platinum-based chemotherapy (like cisplatin or carboplatin) and it stopped working or never fully worked.
- You need at least one tumor that can be measured on a scan.
- You must be in fairly good health—able to take care of yourself and do light activities (ECOG score 0 or 1).
- Your fasting triglyceride (blood fat) level must be below 300 mg/dL.
- You cannot have certain other cancers, active infections, or eye problems like night blindness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests a new targeted drug (limertinib) plus chemotherapy (carboplatin and etoposide) for people whose EGFR-mutant lung cancer has changed into small cell lung cancer (SCLC) after prior targeted therapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This Phase 1/2 study tests lunbotinib, a new medicine that targets a specific lung-cancer change called RET. It aims to see how well it works and how safe it is for adults with advanced RET-altered non-small cell lung cancer.
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.